The use of telmisartan in the treatment of arterial hypertension with obesity
DOI:
https://doi.org/10.24959/cphj.18.1447Keywords:
arterial hypertension, obesity, hemodynamics, lipids, telmisartanAbstract
The combined course of arterial hypertension (AH) with overweight or abdominal obesity is considered as one of the most common type of comorbid pathology leading to a significant increase of cardiovascular complications.
Aim. To study the effects of telmisartan on the intracardiac hemodynamics, the functional state of the myocardium, the lipid and carbohydrate profile in patients with arterial hypertension (AH) and obesity.
Materials and methods. 50 patients with AH of stage II were examined, they were divided into 2 groups. The first (main) group consisted of 23 patients with stage II arterial hypertension and the normal body weight. In the second
group (reference group) there were 27 patients, who were diagnosed with AH of stage II and obesity. The diagnosis was verified using laboratory instrumental methods in accordance with the recommendations of the European Cardiologic Society (2013). Obesity was assessed by the body mass index and the waist to the hip ratio. The lipid profile was determined by the enzymatic method.
Results. It has been found in the study that the level of values of systolic blood pressure (SBP) in hypertensive patients with the normal body weight treated with telmisartan decreased by 14.5 %, while diastolic blood pressure (DBP) reduced by 11.4 %. In patients with AH of stage II having obesity the SBP level also decreased by 13.4 % and DBP – by 11.5 %. In 3 months of treatment the regression dynamics of the end-diastolic and end-systolic dimensions of the heart in the group of patients without obesity led to a significant decrease in these parameters compared to the baseline values. In obese patients these indicators also decreased; however, they did not reach reliable values. When treating with telmisartan there was a decrease in lipids in AH patients (total cholesterol (TC)– (5.5 %), cholesterol of low density lipoproteins (LDL) – 6.2 %, triglycerides (TG) 7.8 %, cholesterol of HDL – by 10.4 % (p <0.05), there were also unreliable changes in AH patients associated with obesity (total cholesterol – by 5.9 %, LDL – 5.1 %, TG – 8.8 % and increased cholesterol of HDL – by 6.4 %). After the treatment the indicators of carbohydrate metabolism decreased (glycosylated hemoglobin (HbA1c) by 8.45 % and 19.17 %, insulin – by 3.2 % and 13.38 % glucose – by 5.65 % and 4.73 %, respectively, in groups).
Conclusions. The study has shown that telmisartan has indirect positive effects on intracardiac hemodynamics due to decrease of blood pressure both in AH patients having the normal body weight and patients with obesity. The use of telmisartan as an antihypertensive agent gives a hypolipidemic effect, improves the parameters of the carbohydrate metabolism in AH patients with the normal body weight and with obesity. These data can be markers for assessing the effectiveness of hypotensive therapy with telmisartan.
References
Svіshchenko, Ye. P., Bahrіi, A. Ye., Yena, L. M. (2012). Novosti meditciny i farmatcii, 12 (422), 12–58.
Spalding, K. L. (2008). Dynamics of fat cell turnover in human. Nature, 453, 783–787.
Oishi, Y., Manabe, I., Tobe, K., Tsushima, K., Shindo, T., Fujiu, K., Nagai, R. (2005). Krüppel–like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metabolism, 1 (1), 27–39. doi: 10.1016/j.cmet.2004.11.005
Schäffler, A., Müller–Ladner, U., Schölmerich, J., Büchler, C. (2006). Role of Adipose Tissue as an Inflammatory Organ in Human Diseases. Endocrine Reviews, 27 (5), 449–467. doi: 10.1210/er.2005–0022
Belovol, A. N., Kovaleva, O. N., Popova, S. S., Tveretinov, A. B. (2009). Ozhyrenie v praktike kardiologa i endokrinologa. Ternopol: Ukrmedkniga, 300–301.
Klimov, A. N., Nikulcheva, N. G. (1999). Obmen lipidov i lipoproteidov i ego narusheniia. Sankt–Petersburg: Piter. Kom., 512.
Kobori, H., Nangaku, M., Navar, L. G., Nishiyama, A. (2007). The Intrarenal Renin–Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease. Pharmacological Reviews, 59 (3), 251–287. doi: 10.1124/pr.59.3.3
Kobalava, Zh. D. (2013) Kardiologiia, 12, 83–93.
Giles, T. D., Oparil, S., Silfani, T. N., Wang, A., Walker, J. F. (2007). Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension. The Journal of Clinical Hypertension, 9 (3), 187– 195. doi: 10.1111/j.1524–6175.2007.06395.x
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
